结直肠癌的基因组分析和个性化治疗的未来

IF 2.7 Q3 ONCOLOGY

Colorectal Cancer Pub Date : 2017-06-21 DOI:10.2217/CRC-2016-0017

K. Harada, D. Kaya, Shumei Song, H. Baba, J. Ajani

{"title":"结直肠癌的基因组分析和个性化治疗的未来","authors":"K. Harada, D. Kaya, Shumei Song, H. Baba, J. Ajani","doi":"10.2217/CRC-2016-0017","DOIUrl":null,"url":null,"abstract":"New technologies have enabled faster, cheaper and more accurate genomic and other types of profiling. Therefore, treatment has become more customized according to molecular subtype. Here, we summarize the current status of genomic profiling for colorectal cancer (CRC) and discuss future directions. Recently, the CRC Subtyping Consortium classified CRC into four subtypes: CMS1, microsatellite instability immune (14%); CMS2, canonical (37%); CMS3, metabolic (13%); and CMS4, mesenchymal (23%). Testing for KRAS, NRAS and BRAF mutations, and microsatellite instability status in CRC has proven essential for treatment decisions. Tumor heterogeneity and the evolution of drug-resistant subclones after therapy should be further assessed and pursued. Patient-derived xenografts and liquid biopsies might facilitate the development of optimum and accurate personalized therapy regimens.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"11-22"},"PeriodicalIF":2.7000,"publicationDate":"2017-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2016-0017","citationCount":"1","resultStr":"{\"title\":\"Genomic profiling of colorectal cancers and the future of personalized treatment\",\"authors\":\"K. Harada, D. Kaya, Shumei Song, H. Baba, J. Ajani\",\"doi\":\"10.2217/CRC-2016-0017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"New technologies have enabled faster, cheaper and more accurate genomic and other types of profiling. Therefore, treatment has become more customized according to molecular subtype. Here, we summarize the current status of genomic profiling for colorectal cancer (CRC) and discuss future directions. Recently, the CRC Subtyping Consortium classified CRC into four subtypes: CMS1, microsatellite instability immune (14%); CMS2, canonical (37%); CMS3, metabolic (13%); and CMS4, mesenchymal (23%). Testing for KRAS, NRAS and BRAF mutations, and microsatellite instability status in CRC has proven essential for treatment decisions. Tumor heterogeneity and the evolution of drug-resistant subclones after therapy should be further assessed and pursued. Patient-derived xenografts and liquid biopsies might facilitate the development of optimum and accurate personalized therapy regimens.\",\"PeriodicalId\":43638,\"journal\":{\"name\":\"Colorectal Cancer\",\"volume\":\"6 1\",\"pages\":\"11-22\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2017-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/CRC-2016-0017\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Colorectal Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/CRC-2016-0017\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colorectal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/CRC-2016-0017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

摘要

新技术实现了更快、更便宜、更准确的基因组和其他类型的分析。因此，根据分子亚型，治疗变得更加个性化。在此，我们总结了癌症（CRC）基因组图谱的现状，并讨论了未来的发展方向。最近，CRC亚型联合会将CRC分为四种亚型：CMS1、微卫星不稳定免疫（14%）；CMS2，规范型（37%）；CMS3，代谢（13%）；和CMS4，间充质（23%）。CRC中KRAS、NRAS和BRAF突变以及微卫星不稳定状态的检测已被证明对治疗决策至关重要。肿瘤异质性和治疗后耐药亚克隆的演变应进一步评估和追踪。患者来源的异种移植物和液体活检可能有助于开发最佳和准确的个性化治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Genomic profiling of colorectal cancers and the future of personalized treatment

New technologies have enabled faster, cheaper and more accurate genomic and other types of profiling. Therefore, treatment has become more customized according to molecular subtype. Here, we summarize the current status of genomic profiling for colorectal cancer (CRC) and discuss future directions. Recently, the CRC Subtyping Consortium classified CRC into four subtypes: CMS1, microsatellite instability immune (14%); CMS2, canonical (37%); CMS3, metabolic (13%); and CMS4, mesenchymal (23%). Testing for KRAS, NRAS and BRAF mutations, and microsatellite instability status in CRC has proven essential for treatment decisions. Tumor heterogeneity and the evolution of drug-resistant subclones after therapy should be further assessed and pursued. Patient-derived xenografts and liquid biopsies might facilitate the development of optimum and accurate personalized therapy regimens.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Colorectal Cancer ONCOLOGY-

自引率

0.00%

发文量

期刊介绍： Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Consequently, colorectal cancer is a major research priority for government, pharmaceutical companies and non-profit organizations. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary. on all aspects of colorectal cancer.